NEW YORK, Sept. 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced that Michael S. Weiss, the Company’s Chairman & Chief Executive Officer, is scheduled to present at the Bear Stearns 20th Annual Healthcare Conference being held at the Grand Hyatt Hotel in New York City. Mr. Weiss’ presentation will take place on Monday, September 10th at 1:30 pm ET.
Mr. Weiss’ presentation will be webcast live and will be accessible from the Investor Information page of the Company’s Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx’s lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965
Keryx Biopharmaceuticals, Inc.
CONTACT: Lauren Fischer, Director - Investor Relations, KeryxBiopharmaceuticals, Inc., +1-212-531-5965
Web site: http://investors.keryx.com/
